RSV patients treated with antiviral drug S-337395 showed statistically significant reduction in viral load S-337395 is ...

LONDON - Shionogi & Co., Ltd ... oral antiviral candidate targeting Respiratory Syncytial Virus (RSV), conducted by hVIVO plc, a leader in human challenge clinical trials. The trial revealed ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a biotechnology company focused on developing small molecule drugs for viral infections and liver diseases, is navigating a critical phase in its evolution.

A digital therapeutic (DTx) for attention deficit hyperactivity disorder (ADHD) developed by Akili has been approved in Japan, where it will be sold by licensee Shionogi. The DTx – known as ...

While Pfizer's discontinuation of sisunatovir may have reduced immediate competition, other players like Ark and Shionogi are still advancing their RSV programs. Enanta must demonstrate clear ...

The oral drug Xocova marks the first home-grown medication, developed by Shionogi & Co., which can be prescribed for patients with mild symptoms, suggesting a stable supply of the tablet will be ...

Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hyperactivity disorder (ADHD ...